Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. (https://pubmed.ncbi.nlm.nih.gov/38418879/)

These scientists wanted to understand how a new medicine called tiragolumab works when combined with another medicine called atezolizumab to treat cancer. They found that patients with a high number of certain immune cells in their tumors had better results when they received both medicines together. When they studied blood samples from these patients, they saw that activating these immune cells was linked to better outcomes.

To understand how tiragolumab works, the scientists studied mice with tumors. They found that tiragolumab helps activate certain immune cells in the tumors, which then help other immune cells fight the cancer better. This research shows how tiragolumab can change the environment inside the tumor to make it easier for the immune system to fight the cancer. It also suggests that how tiragolumab interacts with certain receptors on immune cells is important for its effectiveness.

Guan X., Hu R., Choi Y., Srivats S., Nabet BY., Silva J., McGinnis L., Hendricks R., Nutsch K., Banta KL., Duong E., Dunkle A., Chang PS., Han CJ., Mittman S., Molden N., Daggumati P., Connolly W., Johnson M., Abreu DR., Cho BC., Italiano A., Gil-Bazo I., Felip E., Mellman I., Mariathasan S., Shames DS., Meng R., Chiang EY., Johnston RJ., Patil NS. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature. 2024 Feb 28. doi: 10.1038/s41586-024-07121-9.